Duloxetine for the Treatment of Dysthymia
The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : duloxetine
Ages Eligible For Study:
: - Sign an informed consent form - 18 years of age or older - Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception - Meet DSM-IV criteria for dysthymia - A screening IDS-C score of 17 or greater - No history of serious or unstable medical disorder - Not taking any significant concurrent medications - Not currently receiving psychotherapy